EP1687029A4 - Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance - Google Patents

Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance

Info

Publication number
EP1687029A4
EP1687029A4 EP03816309A EP03816309A EP1687029A4 EP 1687029 A4 EP1687029 A4 EP 1687029A4 EP 03816309 A EP03816309 A EP 03816309A EP 03816309 A EP03816309 A EP 03816309A EP 1687029 A4 EP1687029 A4 EP 1687029A4
Authority
EP
European Patent Office
Prior art keywords
human antibodies
anthrax toxin
neutralizing human
toxin generated
recall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03816309A
Other languages
German (de)
English (en)
Other versions
EP1687029A1 (fr
Inventor
Phillip R Morrow
Angray S Kang
Fei Wang
Ivy Jiang
Ritsuko Sawada-Hirai
Wolfgang Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Priority to EP20120175602 priority Critical patent/EP2570433A1/fr
Publication of EP1687029A1 publication Critical patent/EP1687029A1/fr
Publication of EP1687029A4 publication Critical patent/EP1687029A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP03816309A 2003-11-14 2003-11-14 Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance Withdrawn EP1687029A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20120175602 EP2570433A1 (fr) 2003-11-14 2003-11-14 Neutralisation d'anticorps humains à la toxine de l'anthrax générés par une technologie de concordance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/036555 WO2005056052A1 (fr) 2003-11-14 2003-11-14 Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance

Publications (2)

Publication Number Publication Date
EP1687029A1 EP1687029A1 (fr) 2006-08-09
EP1687029A4 true EP1687029A4 (fr) 2007-05-30

Family

ID=34676210

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20120175602 Withdrawn EP2570433A1 (fr) 2003-11-14 2003-11-14 Neutralisation d'anticorps humains à la toxine de l'anthrax générés par une technologie de concordance
EP03816309A Withdrawn EP1687029A4 (fr) 2003-11-14 2003-11-14 Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20120175602 Withdrawn EP2570433A1 (fr) 2003-11-14 2003-11-14 Neutralisation d'anticorps humains à la toxine de l'anthrax générés par une technologie de concordance

Country Status (5)

Country Link
EP (2) EP2570433A1 (fr)
JP (1) JP4690196B2 (fr)
AU (1) AU2003304600A1 (fr)
CA (1) CA2545714C (fr)
WO (1) WO2005056052A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
ATE530196T1 (de) * 2004-03-03 2011-11-15 Iq Therapeutics Bv Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung
EP1919504B1 (fr) 2005-08-03 2013-10-16 iBio, Inc. Anticorps diriges contre l'antigene protecteur de bacillus anthracis
WO2008048344A2 (fr) 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
AU2007259329A1 (en) * 2006-05-12 2007-12-21 Farris, Darise Anthrax compositions and methods of use and production
CA2692933C (fr) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Antigenes yersinia pestis, compositions de vaccins, et methodes associees
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
WO2011041391A1 (fr) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Anticorps dirigés contre l'hémagglutinine du virus de la grippe, compositions, et procédés associés
WO2018226824A1 (fr) * 2017-06-06 2018-12-13 Indevr, Inc. Analyse simultanée in vitro de la puissance d'un vaccin et de la concentration de toxines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0779795A (ja) * 1993-07-21 1995-03-28 Takeda Chem Ind Ltd ヒトモノクローナル抗体産生株の製造法
US20020001798A1 (en) * 1995-06-07 2002-01-03 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
JP2006503547A (ja) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 生物兵器防衛のための免疫療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0779795A (ja) * 1993-07-21 1995-03-28 Takeda Chem Ind Ltd ヒトモノクローナル抗体産生株の製造法
US20020001798A1 (en) * 1995-06-07 2002-01-03 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. KEARNEY ET AL.: "A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.", THE JOURNAL OF IMMUNOLOGY, vol. 123, no. 4, October 1979 (1979-10-01), pages 1548 - 1550, XP001194440 *
LITTLE S F ET AL: "Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.", INFECTION AND IMMUNITY JUL 1988, vol. 56, no. 7, July 1988 (1988-07-01), pages 1807 - 1813, XP002959465, ISSN: 0019-9567 *
See also references of WO2005056052A1 *

Also Published As

Publication number Publication date
EP2570433A1 (fr) 2013-03-20
JP4690196B2 (ja) 2011-06-01
AU2003304600A1 (en) 2005-06-29
CA2545714A1 (fr) 2005-06-23
CA2545714C (fr) 2012-10-16
JP2007525145A (ja) 2007-09-06
WO2005056052A1 (fr) 2005-06-23
EP1687029A1 (fr) 2006-08-09

Similar Documents

Publication Publication Date Title
HRP20160875T1 (hr) Humana anti-b7rp1 neutralizirajuća antitijela
IL165256A0 (en) Neutralizing human anti-igfr antibody
TWI365883B (en) Antibodies to m-csf
IL191340A (en) Monoclonal antibodies against e8o
EP1591527A4 (fr) Substance specifique a pd-1 humain
IL189788A0 (en) Human monoclonal antibodies to cd70
GB0320283D0 (en) Improvements relating to lancets
EP1638750A4 (fr) Procedes de production de feuilles de gel
ZA200802641B (en) Human monoclonal antibodies to CD70
IL172511A0 (en) Specific human antibodies
EP1598368A4 (fr) Anticorps de neutralisation anti-pci
EP1687029A4 (fr) Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance
HK1216427A1 (zh) 針對 的人抗體分子
ZA200804254B (en) Human monoclonal antibodies to O8E
PL377592A1 (pl) Fragmenty w pełni ludzkiego przeciwciała Fab o działaniu neutralizującym aktywność ludzkiego interferonu-gamma
EP1560595A4 (fr) Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain
GB0300454D0 (en) Human excrement collector

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070427

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

17Q First examination report despatched

Effective date: 20100702

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/12 20060101AFI20120417BHEP

Ipc: A61K 39/40 20060101ALI20120417BHEP

Ipc: A61K 39/395 20060101ALI20120417BHEP

Ipc: C12P 21/08 20060101ALI20120417BHEP

Ipc: A61P 31/04 20060101ALI20120417BHEP

Ipc: C07K 16/00 20060101ALI20120417BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121120